Disease specific brain capillary angiopathy in schizophrenia, bipolar disorder, and Alzheimer's disease

Shinobu Hirai1, Atsuhiro Sakuma1, Yasuto Kunii2

  • 1Brain Metabolic Regulation Group, Frontier Laboratory, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.

Insights

Brain capillary damage, indicated by fibrin accumulation, is common in schizophrenia and bipolar disorder. This finding offers new diagnostic and therapeutic avenues for these psychiatric conditions.

Area of Science:

  • Neuroscience
  • Pathology
  • Vascular Biology

Background:

  • Schizophrenia (SZ) and bipolar disorder (BD) share clinical symptoms.
  • Brain capillary angiopathy, marked by fibrin accumulation, is a newly identified common feature in SZ and BD.

Purpose of the Study:

  • To investigate similarities and differences in cerebral capillary injury across various brain diseases.
  • To explore potential new diagnostic methods and therapeutic strategies for SZ and BD.

Main Methods:

  • Postmortem brain tissue analysis was used to evaluate vascular damage.
  • Fibrin accumulation in grey matter (GM) and white matter (WM) capillaries was quantified.
  • Comparison was made between patients with SZ, BD, amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), and control subjects.

Main Results:

  • Significant fibrin accumulation was observed in the GM capillaries of SZ and AD patients.
  • Fibrin accumulation was noted in the WM capillaries of SZ, BD, and AD patients.
  • ALS and PD brains showed no significant fibrin accumulation; AD brains exhibited fibrin leakage into the parenchyma.

Conclusions:

  • Fibrin accumulation in brain capillaries is characteristic of SZ, BD, and AD.
  • A non-disruptive fibrin-accumulating angiopathy distinguishes SZ and BD, with regional variations observed.

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
106
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
541
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
778
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
144
The Blood-brain Barrier00:49

The Blood-brain Barrier

Overview
47.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
226